RPS6KA3 and metastatic malignant neoplasm: They concluded that fascin-1 is expected to become a prognostic marker of metastatic cancer, and RSK2-CREB-fascin-1 signaling pathway is expected to become a therapeutic target of metastatic cancer (67).